Sales of the HIV drug Fuzeon grew 17 percent in the third quarter of this year, biopharma firm Trimeris (Nasdaq: TRMS) reported Monday after the markets closed.
For the quarter ending September 30, Fuzeon sales rose to $73.9 million compared to $63 million in the same quarter a year ago.
Sales in the United States and Canada did decline 9 percent from 2006, but that setback was more than made up by a 47 percent jump in sales elsewhere. U.S./Canada sales dipped to $30.6 million from $33.5 million a year earlier but international sales soared to $43.3 million from $29.5 million.
Fuzeon is sold by Roche, Trimeris’ development, manufacturing, marketing and sales partner.
Through the first nine months of this year, Fuzeon sales reached $200.3 million, up 14 percent from 2006
